Microbiota diversity of infant faecal samples in Europe, Asia, Mexico and Russia
Completed
- Conditions
- Presence of pathogens or absence of healthy faecal microfloraDigestive SystemPresence of pathogens in faecal microflora
- Registration Number
- ISRCTN37114076
- Lead Sponsor
- Royal Friesland Foods B.V. (Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
1. Healthy infants
2. Infants born through natural delivery
3. Informed consent
4. Infants from middle class parents
5. Exclusively formula-fed infants
6. Either male or female, aged 2 weeks up to ca. 12 months
Exclusion Criteria
1. Allergic infants
2. Infants born through caesarean section
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Distribution of microbial species in faecal samples correlated to region.
- Secondary Outcome Measures
Name Time Method Impact of geographic location on presence of microbial pathogens, and also bifidobacteria, lactobacilli, and other microbial species.<br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link infant gut microbiota diversity to pathogen presence in ISRCTN37114076?
How does faecal microbiota composition in ISRCTN37114076 compare to other global infant populations?
Are specific gut microbiota biomarkers associated with healthy digestive development in European infants from ISRCTN37114076?
What adverse events are reported in longitudinal infant gut microbiome studies like ISRCTN37114076?
How do probiotic interventions compare to natural microbiota development in preventing pathogen colonization in infants?